Use and perceived utility of [ 18 F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022

作者：Valentina Ambrosini, Martyn Evan Caplin, Justo Pastor Castano, Emanuel Christ, Timm Denecke, Christophe M. Deroose, Clarisse Dromain, Massimo Falconi, Simona Grozinsky‐Glasberg, Rodney John Hicks, Johannes Hofland, Andreas Kjær, Ulrich Knigge, Beata Kos‐Kudła, Anna A. Koumarianou, B A Rama Krishna, Ángela Lamarca, Marianne Pavel, Nicholas Simon Reed, Aldo Scarpa, Rajaventhan Srirajaskanthan, Anders Sundin, Christos Toumpanakis, Vikas Prasad · 发表于：Journal of Neuroendocrinology · 年份：2023 · DOI：10.1111/jne.13359 · 被引用次数：26 · 研究领域：Neuroendocrine Tumor Research Advances、Neuroblastoma Research and Treatments、Lung Cancer Research Studies

Somatostatin receptor (SST) PET/CT is the gold standard for well-differentiated neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms (NEN) show preferential [18F]FDG (FDG) uptake, and even low-grade NET may de-differentiate over time. FDG PET/CT's prognostic role is widely accepted; however, its impact on clinical decision-making remains controversial and its use varies widely. A questionnaire-based survey on FDG PET/CT use and perceived decision-making utility in NEN was submitted to the ENETS Advisory Board Meeting attendees (November 2022, response rate = 70%). In 3/15 statements, agreement was higher than 75%: (i) FDG was considered useful in NET, irrespective of grade, in case of mis-matched lesions (detectable on diagnostic CT but negative/faintly positive on SST PET/CT), especially if PRRT is contemplated (80%); (ii) in NET G3 if curative surgery is considered (82%); and (iii) in NEC prior to surgery with curative intent (98%). FDG use in NET G3, even in the presence of matched lesions, as a baseline for response assessment was favoured by 74%. Four statements obtained more than 60% consensus: (i) FDG use in NET G3 if locoregional therapy is considered (65%); (ii) in neuroendocrine carcinoma before initiating active therapy as a baseline for response assessment (61%); (iii) biopsy to re-assess tumour grade prior to a change in therapeutic management (68%) upon detection of FDG-positivity on the background of a prior G1-2 NET; (iv) 67% were in...